Trouble reading this email? View it in your browser
European Federation of Pharmaceutical industries and associations

EFPIA Newsletter 8 May 2024


Realising the potential of HTA Reform

By Nathalie Moll, Director General, EFPIA

The HTA Regulation was intended to streamline how the value of medicines is assessed, but by overburdening the process, it risks making patients wait for new therapies. Now is the time to come together to ensure we can realise the potential of the EU HTA reform for patients.


Read more


From our blog

More than half of the direct expenditure on diabetes is associated with complications (Guest blog)


In the 2019-2022 period the average annual expenditure on diabetes amounted to 174 million euros. The average annual growth rate of direct spending on diabetes and its complications was 12.5 percent over the period studied.


"For me as a diabetologist, the key message is that significant resources are spent on treating the chronic complications of diabetes, so it would make sense to redirect as much of this money as possible to preventing these complications so that money can be spent on people who are still healthy and maintaining their health," commented Prof. Dr. Tadej Battelino.


Read more here.



Rare Disease Moonshot: breaking down barriers to accelerate research

The Rare Disease (RD) Moonshot was set up to boost public private collaborations in the areas where there are no treatment options and there is no R&D going on.


The RD Moonshot partners put together three sets of recommendations to highlight where public-private collaborations can add most value.


Click here to learn more on the recommendations for accelerating translational research for rare diseases.





GetReal Conference 2024 A Growing Convergence: RWE for Regulatory and HTA Decision-Making
14 May 2024 (Utrecht, The Netherlands)

A Growing Convergence: RWE for Regulatory and HTA Decision-Making Read more

12th European Conference on Rare Disease & Orphan Products
15 May 2024 (Hybrid - Brussels and Online)

The ECRD is the largest, patient-led, rare disease policy-shaping event held in Europe. Read more

IMI impact on antimicrobial resistance
31 May 2024 (Online event)

Combatting antimicrobial resistance: the legacy of the IMI COMBACTE projects. Read more

Countdown to the EU HTA: how can we seize this opportunity to improve patient access to medicines?...
04 June 2024 (Online session)

In January 2025, all new cancer medicines and advanced therapy medicinal products (ATMPs) will be jointly assessed at... Read more


What we are reading

Does the EU need an immunisation strategy?
On 08 May 2024 (Euractiv)

Euractiv spoke with Laurent Louette, the director of public affairs and countries liaison at Vaccines Europe about... Read more

Belgian innovative pharma sector urges government to prioritise competitiveness
On 07 May 2024 (Euractiv)

The Belgian innovative pharmaceutical industry continues to grow, but competitiveness dynamics... Read more

Europe’s amputation crisis, diabetes experts call for urgent new screening programs
On 01 May 2024 (Euractiv)

Europeans suffer 100,000 amputations a year because of the escalating issue of ‘diabetic foot’.

Read more